PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29320658
OWN - NLM
STAT- MEDLINE
DCOM- 20180112
LR  - 20180112
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 2
DP  - 2018 Jan 11
TI  - Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer.
PG  - 192-193
LID - 10.1056/NEJMe1714580 [doi]
FAU - Popat, Sanjay
AU  - Popat S
AD  - From the Department of Medicine, Royal Marsden Hospital, and the Section of
      Genomic Medicine, National Heart and Lung Institute, Imperial College, London.
LA  - eng
PT  - Editorial
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Piperazines)
RN  - 3C06JJ0Z2O (osimertinib)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - AIM
SB  - IM
CON - N Engl J Med. 2018 Jan 11;378(2):113-125. PMID: 29151359
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - Humans
MH  - *Lung Neoplasms
MH  - Piperazines
MH  - Receptor, Epidermal Growth Factor
EDAT- 2018/01/11 06:00
MHDA- 2018/01/13 06:00
CRDT- 2018/01/11 06:00
PHST- 2018/01/11 06:00 [entrez]
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
AID - 10.1056/NEJMe1714580 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Jan 11;378(2):192-193. doi: 10.1056/NEJMe1714580.